Global private equity and venture capital news and research

TPG succeeds in $2.9bn Aptalis sale months after deal looked dead

9 Jan 2014

drug-pharma-medical-healthcareTPG Capital has sold drugmaker Aptalis Pharma for $2.9bn to Forest Laboratories just months after the sale process looked to have stalled.

Sorry, to get access to this you need to subscribe for free.

In order to view more content, sign-up to our free daily newsletter.

If you would like to read the premium stories, have complete access to our breaking news and Limited Partner magazine you need to become a Premium Subscriber.

Subscribe to AltAssets today

Login to AltAssets

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016